Search research articles
Contact Us
Filters
Showing results (201-210 of 218) with videos related to
Page
of 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 16, 2014
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization
Ann L White, Lang Dou, H T Claude Chan, et al.
Leukemia
|
December 18, 2019
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
Francesco Cucco, Sharon Barrans, Chulin Sha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
Andrew J Davies, Sharon Barrans, Louise Stanton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
Chulin Sha, Sharon Barrans, Francesco Cucco, et al.
Cancer Cell
|
December 16, 2014
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies
Ann L White, H T Claude Chan, Ruth R French, et al.
The Journal of Pathology. Clinical Research
|
June 28, 2016
The prognosis of <i>MYC</i> translocation positive diffuse large B-cell lymphoma depends on the second hit
Alexandra Clipson, Sharon Barrans, Naiyan Zeng, et al.
The Lancet. Oncology
|
April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial
Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli, et al.
Leukemia
|
August 30, 2019
BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
Lindsay D Smith, Annabel R Minton, Matthew D Blunt, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 218) with videos related to
Sort By:
Page
of 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 16, 2014
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization
Ann L White, Lang Dou, H T Claude Chan, et al.
Leukemia
|
December 18, 2019
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
Francesco Cucco, Sharon Barrans, Chulin Sha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
Andrew J Davies, Sharon Barrans, Louise Stanton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
Chulin Sha, Sharon Barrans, Francesco Cucco, et al.
Cancer Cell
|
December 16, 2014
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies
Ann L White, H T Claude Chan, Ruth R French, et al.
The Journal of Pathology. Clinical Research
|
June 28, 2016
The prognosis of <i>MYC</i> translocation positive diffuse large B-cell lymphoma depends on the second hit
Alexandra Clipson, Sharon Barrans, Naiyan Zeng, et al.
The Lancet. Oncology
|
April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial
Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli, et al.
Leukemia
|
August 30, 2019
BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
Lindsay D Smith, Annabel R Minton, Matthew D Blunt, et al.
Page
of 22